Thelansis

B-Acute Lymphocytic Leukemia (ALL) Market Outlook Thelansis’s “B-Acute Lymphocytic Leukemia (ALL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential B-Acute Lymphocytic Leukemia (ALL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

  B-cell acute lymphoblastic leukemia (ALL) is a type of blood cancer in which many abnormal, immature lymphocytes known as blasts begin to multiply in the bone marrow. Lymphocytes are white blood cells that play a role in the immune response. B-ALL is characterized by the expression of various B–cell-specific antigens, which often include PAX-5, CD19, CD20, CD22, CD24, and CD79a. B-cell ALL is primarily a childhood disease, with approximately 75% of cases being children aged <6 years; however, the majority of B-cell ALL occurs in the <15 years of age; also, the peak of the incidence is seen in people around 40 years. Approximately 20% to 30% of adult acute lymphoblastic leukemias (ALLs) and 5% of pediatric ALLs harbor the Ph-chromosome. This genetic alteration confers a poor prognosis, as defined by shorter remission duration, shorter survival, and higher rates of resistance to standard chemotherapy. CNS involvement is more common in relapsed adult patients. In children, t...